Simulations Plus Sets Date For 4th Quarter And Fiscal Year 2016 Earnings Release And Conference Call

Simulations Plus, Inc. (Nasdaq: SLP) announced today that it expects to file Form 10-K for the 2016 fiscal year ended August 31, 2016, with the U.S. Securities and Exchange Commission on November 14, 2016.

Walt Woltosz, chairman and CEO, and Ted Grasela, president, will host a conference call to discuss the Company's performance on Friday, November 11, 2016, at 4:15 p.m. Eastern Time. All interested parties are invited to join the call by registering at: https://attendee.gotowebinar.com/register/7098520015199435521. On registering, you will receive a confirmation e-mail with instructions for joining the call. Please dial in five to ten minutes prior to the scheduled start time. For listen-only mode, you may dial +1 (415) 930-5321, and enter access code: 591-425-045.

About Simulations Plus, Inc.

Simulations Plus, Inc. is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com.

If you liked this article you might like

Market Can't Sustain Upside Push

10 High-Growth Health Care Stocks to Buy Now

Mid-Cap A+ Rated Stocks That Pay High Dividends

12 'A+' Rated Stocks With Great Growth Potential and High Return on Invested Capital

20 A+ Rated Mid-Cap Growth Stocks